The comprehensive therapeutic effects of rectal surgery are better in laparoscopy: a systematic review and meta-analysis

Background/Aims: Coronary heart disease is characterized by vascular stenosis or occlusion resulting in myocardial ischemia, hypoxia and necrosis. In China, the combination of aspirin and Fufang Danshen Diwan (FDD), a traditional Chinese medicine formula, has been suggested in the treatment of coronary heart disease. There have been several studies comparing the effectiveness of aspirin alone and in combination with FDD to treat coronary artery disease; however, it remains unclear whether combined aspirin therapy is superior. This study was thus designed to clarify this issue through a systematic review and meta-analysis. Methods: Databases including PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) database, Wanfang Data and VIP Information were searched. Papers were reviewed systematically by two researchers and analyzed using Cochrane software Revman 5.1. Results: Fourteen randomized controlled trials enrolling 1367 subjects were included. Meta-analyses revealed that aspirin in combination with FDD was significantly more effective at alleviating angina pectoris and improving electrocardiogram (ECG) results relative to aspirin therapy alone, reflected by the summary effects for the clinical markedly effective (OR = 2.45; 95% CI 1.95-3.08) and the total effective (OR = 3.92; 95% CI 2.87-5.36) rates. In addition, combined aspirin and FDD was significantly more efficacious than aspirin monotherapy at improving blood lipid levels, as indicated by the following outcomes: 1) reduction of TC level (SMD −1.12; 95% CI −1.49 to −0.76); 2) reduction of TG level (SMD −0.94; 95% CI −1.15 to -0.74); 3) reduction of LDL level (SMD -0.68; 95% CI -0.88 to -0.48); and 4) improvement of HDL level (SMD 0.52; 95% CI 0.04 to 0.99 ). No serious adverse events were reported in any of the included trials. Conclusion: The present meta-analysis demonstrated that aspirin in combination with FDD was more effective than aspirin alone for treating coronary heart disease. More full-scale randomized clinical trials with reliable designs are recommended to further evaluate the clinical benefits and long-term effectiveness of FDD for the treatment of coronary heart disease.

Download Full-text

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder

CNS Spectrums ◽

10.1017/s1092852918001050 ◽

2018 ◽

Vol 24 (5) ◽

pp. 479-495 ◽

Cited By ~ 4

Author(s):

Marco Solmi ◽

Michele Fornaro ◽

Kuniyoshi Toyoshima ◽

Andrè F. Carvalho ◽

Cristiano A. Köhler ◽

...

Keyword(s):

Systematic Review ◽

Problem Solving ◽

Executive Functions ◽

Negative Symptoms ◽

Biological Effects ◽

Meta Analysis ◽

Cortical Activation ◽

Therapeutic Effects ◽

Double Blind ◽

Relapse Prediction

ObjectiveOur aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.MethodsWe undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.ResultsWe included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimulants or atomoxetine. No effect resulted from interventional studies on weight loss (k=1), smoking cessation (k=1), and positive symptoms (k=12), and no improvement was reported with atomoxetine (k=3) for negative symptoms, with equivocal findings for negative (k=6) and mood symptoms (k=2) with amphetamines. Attention, processing speed, working memory, problem solving, and executive functions, among others, showed from no to some improvement with atomoxetine (k=3) or amphetamines (k=6). Meta-analysis did not confirm any effect of stimulants in any symptom domain, including negative symptoms, apart from atomoxetine improving problem solving (k=2, standardized mean difference (SMD)=0.73, 95% CI=0.10–1.36,p=0.02, I2=0%), and trending toward significant improvement in executive functions with amphetamines (k=2, SMD=0.80, 95% CI=−1.68 to +0.08,p=0.08, I2=66%). In challenge studies, amphetamines (k=1) did not worsen symptoms, and methylphenidate (k=5) consistently worsened or predicted relapse. Biological effects of atomoxetine (k=1) and amphetamines (k=1) were cortical activation, without change in β-endorphin (k=1), improved response to antipsychotics after amphetamine challenge (k=2), and an increase of growth hormone–mediated psychosis with methylphenidate (k=2). No major side effects were reported (k=6).ConclusionsNo efficacy for stimulants or atomoxetine on negative symptoms is proven. Atomoxetine or amphetamines may improve cognitive symptoms, while methylphenidate should be avoided in patients with schizophrenia. Insufficient evidence is available to draw firm conclusions.

Download Full-text

Therapeutic effects of whole-body vibration on fracture healing in ovariectomized rats: a systematic review and meta-analysis

Menopause The Journal of The North American Menopause Society ◽

10.1097/gme.0000000000001285 ◽

2018 ◽

Vol 26 (6) ◽

pp. 677-686 ◽

Cited By ~ 5

Author(s):

Jinman Chen ◽

Hongfeng Ruan ◽

Yang Liu ◽

Jiamin Bao ◽

Hao Xu ◽

...

Keyword(s):

Systematic Review ◽

Fracture Healing ◽

Meta Analysis ◽

Whole Body Vibration ◽

Ovariectomized Rats ◽

Whole Body ◽

Therapeutic Effects ◽

Body Vibration

Download Full-text

Therapeutic effects of acupuncture in typical dry eye: a systematic review and meta‐analysis

Acta Ophthalmologica ◽

10.1111/aos.14651 ◽

2020 ◽

Author(s):

Ji‐Ho Na ◽

Ji‐Hyeo Jung ◽

Joon‐Gon Park ◽

Phil Hyun Song ◽

Chang‐Hyun Song

Keyword(s):

Systematic Review ◽

Dry Eye ◽

Meta Analysis ◽

Therapeutic Effects

Download Full-text

The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis

Rheumatology ◽

10.1093/rheumatology/kez311 ◽

2019 ◽

Vol 59 (5) ◽

pp. 959-967 ◽

Cited By ~ 3

Author(s):

Takashi Shimizu ◽

Takayoshi Morita ◽

Atsushi Kumanogoh

Keyword(s):

Systematic Review ◽

Selection Criteria ◽

Meta Analysis ◽

Clinical Parameter ◽

Ivig Treatment ◽

Therapeutic Effects ◽

Random Effects Model ◽

Anca Associated Vasculitis ◽

Before And After ◽

Meta Analyses

Abstract Objectives The therapeutic effects of IVIG in patients with ANCA-associated vasculitis (AAV) have not been established so far. This study aims to estimate the effects of IVIG on AAV by conducting a systematic review and meta-analysis. Methods A comprehensive systematic review was conducted in accordance with the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews And Meta-analyses). PubMed and Google Scholar were used to search for original studies on AAV and collect clinical data before and after IVIG treatment. A meta-analysis of each clinical parameter was performed, and standardized mean difference (SMD) and 95% CI were calculated using the random effects model. Results A total of 220 studies were identified, and nine met the selection criteria for the meta-analysis. IVIG was administered to active AAV patients as an immunomodulatory therapy in the nine studies selected. Significant reductions in BVAS (SMD –1.7; 95% CI [–2.66, –0.73]; P = 0.0006), ANCA (SMD –0.72; 95% CI [–1.13, –0.31]; P = 0.0006) and CRP (SMD –0.92; 95% CI [–1.49, –0.35]; P = 0.002) were noted within 6 months after administration of IVIG. Subgroup analysis in the unmodified immunotherapy population showed reductions in BVAS (SMD –1.39; 95% CI [–2.31, –0.48]; P = 0.003) and CRP (SMD –0.56; 95% CI [–0.93, –0.19]; P = 0.002) within half a month after IVIG treatment. Conclusion IVIG was associated with rapid improvements in disease activity and the related biomarkers in patients with active AAV.

Download Full-text

The Effects of Metformin on Ovarian Cancer: A Systematic Review

International Journal of Gynecological Cancer ◽

10.1097/igc.0b013e3182a80a21 ◽

2013 ◽

Vol 23 (9) ◽

pp. 1544-1551 ◽

Cited By ~ 31

Author(s):

Piyemeth Dilokthornsakul ◽

Nathorn Chaiyakunapruk ◽

Wichai Termrungruanglert ◽

Chayanin Pratoomsoot ◽

Surasak Saokeaw ◽

...

Keyword(s):

Systematic Review ◽

Ovarian Cancer ◽

Cancer Prevention ◽

Observational Studies ◽

Cancer Survival ◽

Meta Analysis ◽

Progression Free Survival ◽

Survival Outcomes ◽

Diabetic Patients ◽

Therapeutic Effects

ObjectiveThe potential therapeutic effects of metformin on several cancers were reported. However, the evidence of the effects of metformin on ovarian cancer is still limited and inconclusive. This systematic review and meta-analysis study aims to summarize the existing evidence of the therapeutic effects of metformin on ovarian cancer.MethodsWe performed systematic searches using electronic databases including PubMed and EMBASE until December 2012. Key words included “metformin” AND (“ovarian cancer” OR “ovary tumor”). All human studies assessing the effects of metformin on ovarian cancer were eligible for inclusion. All articles were reviewed independently by 2 authors with a standardized approach for the purpose of study, study design, patient characteristics, exposure, and outcomes. The data were pooled using a random-effects model.ResultsOf 190 studies retrieved, only 3 observational studies and 1 report of 2 randomized controlled trials were included. Among those studies, 2 reported the effects of metformin on survival outcomes of ovarian cancer, whereas the other 2 reported the effects of metformin on ovarian cancer prevention. The findings of studies reporting the effects on survival outcomes indicated that metformin may prolong overall, disease-specific, and progression-free survival in ovarian cancer patients. The results of studies reporting the effects of metformin on ovarian cancer prevention were meta-analyzed. It indicated that metformin tended to decrease occurrence of ovarian cancer among diabetic patients with the pooled odds ratio of 0.57 (95% confidence interval, 0.16–1.99).ConclusionsOur findings showed the potential therapeutic effects of metformin on survival outcomes of ovarian cancer and ovarian cancer prevention. However, most of the evidence was observational studies. There is a call for further well-conducted controlled clinical trials to confirm the effects of metformin on ovarian cancer survival and ovarian cancer prevention.

Download Full-text

Mo1782 - Therapeutic Effects and Adverse Events of Tacrolimus on Patients with Crohn's Disease: A Systematic Review and Meta-Analysis

Gastroenterology ◽

10.1016/s0016-5085(18)32746-x ◽

2018 ◽

Vol 154 (6) ◽

pp. S-800

Author(s):

Tomoya Iida ◽

Masanori Nojima ◽

Hiroshi Nakase

Keyword(s):

Systematic Review ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Adverse Events ◽

Meta Analysis ◽

Therapeutic Effects

Download Full-text

Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis

Jornal Brasileiro de Pneumologia ◽

10.1590/s1806-37562016000000287 ◽

2017 ◽

Vol 43 (4) ◽

pp. 302-312 ◽

Cited By ~ 5

Author(s):

Israel Silva Maia ◽

Mariângela Pimentel Pincelli ◽

Victor Figueiredo Leite ◽

João Amadera ◽

Anna Maria Buehler

Keyword(s):

Systematic Review ◽

Adverse Events ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Therapeutic Effects ◽

Muscarinic Antagonists ◽

Serious Adverse Events ◽

Exacerbation Rate ◽

Copd Exacerbations ◽

Long Acting

ABSTRACT Objective: To determine whether long-acting muscarinic antagonists (LAMAs) provide superior therapeutic effects over long-acting β2 agonists (LABAs) for preventing COPD exacerbations. Methods: This was a systematic review and meta-analysis of randomized clinical trials involving patients with stable, moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease criteria, treated with a LAMA (i.e., tiotropium bromide, aclidinium, or glycopyrronium), followed for at least 12 weeks and compared with controls using a LABA in isolation or in combination with a corticosteroid. Results: A total of 2,622 studies were analyzed for possible inclusion on the basis of their title and abstract; 9 studies (17,120 participants) were included in the analysis. In comparison with LABAs, LAMAs led to a greater decrease in the exacerbation rate ratio (relative risk [RR] = 0.88; 95% CI: 0.84-0.93]; a lower proportion of patients who experienced at least one exacerbation (RR = 0.90; 95% CI: 0.87-0.94; p < 0.00001); a lower risk of exacerbation-related hospitalizations (RR = 0.78; 95% CI: 0.69-0.87; p < 0.0001); and a lower number of serious adverse events (RR = 0.81; 95% CI: 0.67-0.96; p = 0.0002). The overall quality of evidence was moderate for all outcomes. Conclusions: The major findings of this systematic review and meta-analysis were that LAMAs significantly reduced the exacerbation rate (exacerbation episodes/year), as well as the number of exacerbation episodes, of hospitalizations, and of serious adverse events.

Download Full-text

Therapeutic effects of Yiqi Huoxue prescription on diabetic nephropathy: a meta-analysis and systematic review

Annals of Palliative Medicine ◽

10.21037/apm-21-1147 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Chun Ye ◽

Lu Gu ◽

Yunlin Feng ◽

Fengling Zhou ◽

Wei She

Keyword(s):

Systematic Review ◽

Diabetic Nephropathy ◽

Meta Analysis ◽

Therapeutic Effects

Download Full-text

Efficacy and Safety of Brucea javanica Oil Emulsion Injection in the Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis

Frontiers in Nutrition ◽

10.3389/fnut.2021.784164 ◽

2021 ◽

Vol 8 ◽

Author(s):

Xinmiao Wang ◽

Heping Wang ◽

Luchang Cao ◽

Jingyuan Wu ◽

Taicheng Lu ◽

...

Keyword(s):

Gastric Cancer ◽

Systematic Review ◽

Conventional Therapy ◽

Meta Analysis ◽

Performance Status ◽

Biomedical Literature ◽

Therapeutic Effects ◽

Efficacy And Safety ◽

Oil Emulsion ◽

Brucea Javanica

Background: Gastric cancer (GC) is one of the most common digestive tract cancers and ranks fifth in the incidence of malignant tumors worldwide. Brucea javanica oil emulsion injection (BJOEI), a Chinese patent medicine extracted from Brucea javanica (Yadanzi in Chinese Pinyin), is widely used as an adjuvant treatment for GC in China. This systematic review and meta-analysis aimed to evaluate the available data on the efficacy and safety of BJOEI in the treatment of GC and assess the quality of the synthesized evidence.Methods: A comprehensive search was performed on PubMed, EMBASE, CENTRAL, Web of Science, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang database and Chinese Scientific Journals Database (VIP database), and other potential resources, such as the Chinese Clinical Trial Registry (ChiCTR) and ClinicalTrials.gov from their inception to July 31, 2021. Randomized controlled trials (RCTs) comparing the therapeutic effects of BJOEI combined with conventional therapy to those of conventional therapy alone were included. We used RevMan 5.3 for data analysis and quality evaluation of the included studies and assessed the evidence quality based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria.Results: Eighteen RCTs involving 1,210 patients were included, and the meta-analysis results demonstrated that compared with the control group (conventional therapy), the experimental group (BJOEI combined with conventional therapy) showed a significantly improved overall response rate (ORR) (risk ratio [RR] = 1.52, 95% CI: 1.36–1.69, P < 0.00001), clinical benefit rate (CBR) (RR = 1.17, 95% CI: 1.11–1.23, P < 0.00001), performance status (RR = 1.72, 95% CI: 1.46–2.01, P < 0.00001), and reduced incidence of the following adverse drug reactions (ADRs): neutropenia, leukopenia, nausea and vomiting, diarrhea, liver damage, hand-foot syndrome, and peripheral sensory nerve toxicity. Subgroup analysis showed that the BJOEI intervention could significantly improve the ORR and CBR in patients with GC when combined with FOLFOX4, XELOX, and other chemotherapeutics.Conclusion: The evidence presented in this study supports the fact that BJOEI combined with conventional chemotherapy provides a statistically significant and clinically important effect in the improvement of ORR, CBR, performance status, and ADR reduction in patients with GC. To further support this conclusion, more rigorously designed, large-scale, and multicenter RCTs are needed in the future.

Download Full-text